Gene differentially expressed in breast and bladder cancer and encoded polypeptides
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.
-
Citations
133 Claims
-
1-99. -99. (canceled)
- 100. An isolated antibody or antigen binding fragment thereof comprising at least one, two, three, four, five, or six complementarity determining regions (CDRs), or a variant(s) thereof, of the murine 1B3 monoclonal antibody, wherein said antibody or antigen binding fragment thereof specifically binds C35.
- 112. An antibody or antigen binding fragment thereof comprising a sequence encoded by a polynucleotide having at least 90% identity to the sequence of SEQ ID NO:
- 115. An antibody or antigen binding fragment thereof comprising a sequence encoded by a polynucleotide having at least 90% identity to the sequence of SEQ ID NO:
-
123. An isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises a variable region selected from the group consisting of the VH region of 1B3 and the VL region of 1B3.
-
124. An isolated antibody or antigen binding fragment thereof that specifically binds to C35, wherein said antibody or antigen binding fragment thereof competitively inhibits the 1B3 murine monoclonal antibody from specifically binding to C35.
-
129. The composition according to claim 129, wherein said cytotoxin is selected from the group consisting of:
- taxol, ricin, doxorubicin, cytochalasin B, gramicidin D, ethidium bromide, etoposide, tenoposide, colchicin, dihydroxy anthracin dione, 1-dehydrotestosterone, and glucocorticoid.
- View Dependent Claims (130)
-
133. A method of producing an antibody or antigen binding fragment thereof that specifically binds C35 comprising:
-
(a) culturing a host cell, wherein said host cell comprises an expression vector, wherein said expression vector comprises a polynucleotide sequence encoding an antibody or antigen binding fragment thereof comprising at least one, two, three, four, five, or six complementarity determining regions (CDRs), or a variant(s) thereof, of the murine 1B3 monoclonal antibody, and wherein said antibody or antigen binding fragment thereof specifically binds C35; and
(b) recovering said antibody or antigen binding fragment thereof from said host cell.
-
Specification